Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM

Kei Muro,Jun Watanabe,Kohei Shitara,Kentaro Yamazaki,Hisatsugu Ohori,Manabu Shiozawa,Hirofumi Yasui,Eiji Oki,Takeo Sato,Takeshi Naito,Yoshito Komatsu,Takeshi Kato,Masamitsu Hihara,Junpei Soeda,Kouji Yamamoto,Kiwamu Akagi,Atsushi Ochiai,Katsuya Tsuchihara,Takayuki Yoshino

ANNALS OF ONCOLOGY（2023）

Cited 0|Views10

No score

Abstract

The PARADIGM primary analysis demonstrated that panitumumab (PAN) significantly improved OS vs bevacizumab (BEV) with mFOLFOX6 in RAS WT and left-sided metastatic colorectal cancer (mCRC). Early tumor shrinkage (ETS) and depth of response (DpR) are on-treatment prognostic factors related to favorable OS and PFS in mCRC chemotherapy. We report ETS and DpR and the correlation with OS and PFS in patients (pts) with RAS WT mCRC from PARADIGM.

Translated text

Key words

early tumor shrinkage,bevacizumab,mfolfox treatment,first-line

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined